He says cardiologists will become increasingly comfortable using GLP-1 RAs and dual agonists, although they need to take care when starting them in patients with diabetes who are taking insulin
At 20mg/mL, doses from 2mg to 12mg all fit in one draw, making it the most versatile concentration for a full dose escalation schedule
Researchers interested in this direction can see more details on the efficacy of GLP-1R/GCGR agonists in the treatment of obesity in Sanchez-Garridos review (131)
The response from many of those employers has been swift: Blue Cross Blue Shield of Massachusetts dropped GLP-1 coverage for obesity treatment for employers with fewer than 100 employees at the start of 2026 Harvard Pilgrim Health Care and Blue Cross Blue Shield of Michigan both dropped weight-loss GLP-1 coverage in 2026 HCA Healthcare one of the countrys largest hospital systems notified employees that its GLP-1 coverage was ending after usage surged 90% in a single year, directing workers instead toward manufacturer cash-pay programs Several other employers have stopped short of elimination but have tightened requirements dramatically restricting coverage only to patients with a formal diabetes diagnosis and removing access for patients using GLP-1s for weight management alone. Why Are Employers Cutting This Coverage Now
GIP (Glucose-dependent insulinotropic peptide): Enhances the secretion of insulin when blood sugar levels rise, further aiding in blood glucose control
Why? Fasting is a common strategy during GLP-1 therapy, but hunger during fasting periods can derail progress
